公司資料
Mustang Bio 股價、新聞與催化劑
- 股票代碼:
- MBIO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.55 USD (+1.91%)
收盤價
最後更新: 2026年9月21日
5.77M USD
市值
股價為何變動
截至 2026年9月21日，MBIO 上漲 1.91%，收於 $0.5500。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.
所在地與產業分類
Mustang Bio is headquartered in the United States and listed on NASDAQ, placing it in the small-cap oncology biotech universe. It sits squarely in development-stage cell therapy rather than commercial large-cap pharma.
商業模式特徵
The company depends on clinical data, manufacturing execution, and access to capital to keep programs moving. Investors usually focus on trial updates, safety and efficacy signals, and whether the platform can survive long enough to reach meaningful commercialization.
生技產業定位
Mustang Bio occupies a high-volatility cell therapy niche within biotech. Because it is still heavily development-driven, the stock tends to respond sharply to readouts, financing, and strategic partnerships.
未來催化劑
- Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum. The stock remains highly data-sensitive.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。